Alchemgen Therapeutics

Alchemgen Therapeutics is a clinical-stage biotechnology company focused on developing next-generation small molecule drugs for immunology and oncology. The company utilizes a proprietary structure-based drug discovery platform to design highly selective inhibitors, aiming to minimize off-target effects and improve patient outcomes. Its lead candidate, AC-002, is a potent and selective TYK2 inhibitor currently being evaluated for the treatment of moderate-to-severe psoriasis and other inflammatory conditions. Beyond its lead program, Alchemgen is advancing a pipeline of novel kinase inhibitors targeting various autoimmune and inflammatory pathways. Headquartered in Taiwan, the company is led by an experienced management team with a proven track record in global drug discovery and development. Alchemgen aims to address significant unmet medical needs by providing best-in-class oral therapies for chronic diseases.